pretickt

Is DVA a good stock to buy?

DaVita Inc. · end-of-day data as of Nov 13, 2026

DaVita
DVA · $10.98B
$174.56+0.3%
Nov 13, 2026 · close
$180$190SepOctNov9:3016:003 months -1.9%Nov 13 · close
▲ 5
  • PT$247.75 +41.9%
  • P/E vs own-10.5%
  • P/E vs sector-57.5%
  • FCF yield+11.8%
  • Sector▲ +15.9%
Neutral
  • Earnings in80d
  • P/E13.7x
  • RSI42
  • Support-11.7%
  • Resistance+0.7%
  • Off 52w high-29.5%
  • Volume0.7x
  • Bollingerlower half
  • News0.00
  • ConsensusHold · 9
  • Trendsideways
  • 52w range$101–$247
  • ATR+4.1%
  • Off ATH-29.5%
  • MA20×50↓ in ~6d
▼ 3
  • Insiders-$69.03M
  • MAs0 of 4
  • MACD-1.49

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is DaVita a good stock to buy?

DaVita is strong on 1 of the 5 questions about the business. The price is about usual: 13.7 times its earnings, near its 3-year median of 14.5 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand steady
  2. Advantage some edge
  3. Economics profitable
  4. Execution delivers
  5. Fragility some risks
  6. Price about usual
DemandDo people want more of what it sells?steady

DVA sales growth revenue growth

+6%a year, for the last 3 years

DaVita's sales grew 6% a year for 3 years, to $13.64B in fiscal 2025.

DVA analysts' forecast revenue estimates

+4%the sales they expect next fiscal year, on the last

Analysts expect DaVita's sales to grow 4% to $14.19B in fiscal 2026 (5 analysts).

DVA peers

pretickt analysis+6%its sales in 12 months, on a year before

DaVita's sales grew 6% in the 12 months to Sep 30, 2026, faster than HCA Healthcare (+6%) and Bio-Techne (+1%), slower than Insulet (+26%) and Universal Health Services (+8%).

Advantage moatIs it hard to copy?some edge

DVA return on capital ROIC

pretickt analysis17%earned before tax on the money invested in it

DaVita earned 17% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Insulet 30%, HCA Healthcare 28%, Universal Health Services 15% and Bio-Techne 11%.

DVA margin on each sale gross margin

31%left after making the product

DaVita kept 31% of each sale after making the product in the 12 months to Sep 30, 2026; its peers' median is 68%.

EconomicsDoes it make good money?profitable

DVA margin after costs profit margin

15%of sales left after running the business

DaVita's operating margin was 15% in the 12 months to Sep 30, 2026, against 12% in fiscal 2022.

DVA cash generated free cash flow

$1.29Bcash left after investing, last 12 months

DaVita generated $1.29B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

ExecutionDoes it deliver what it promises?delivers

DVA earnings vs estimates

7 of 8quarters above the analysts' estimate

DaVita beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Oct 29, 2026.

DVA insider selling

-$523Msold, net, by its executives in 12 months

DaVita's executives and directors sold a net $523M of shares in the 12 months to Nov 13, 2026; none bought.

DVA number of employees

+3%more people in a year

DaVita had 78,000 employees at the end of fiscal 2025, 3% more than a year before.

DVA CEO pay

$18.21Mfor fiscal 2025, 78% of it in stock and options

DaVita paid its CEO $18.21M for fiscal 2025, 78% of it in stock and options.

Fragility risksCould something break it?some risks

DVA financial health Altman Z-score

1.7Altman Z-score, safe above 3

DaVita's Altman Z-score is 1.7 (Nov 13, 2026), below 1.8, the distress zone.

DVA in past recessions

pretickt analysis+1%its sales in the worst one

DaVita's sales grew through each of the last 2 US recessions (2008–09 and 2020).

Price valuationIs the price reasonable?about usual

DVA price vs profit P/E ratio

13.7×a year's earnings

DaVita's P/E ratio is 13.7 (Nov 13, 2026), near its 3-year median of 14.5.

DVA price vs peers

pretickt analysis13.7×a year's earnings, against its peers

Investors pay 13.7 times DaVita's earnings (Nov 13, 2026), more than for Universal Health Services (8.1), less than for Bio-Techne (66.2), Insulet (24.8) and HCA Healthcare (16.5).

DVA analysts' target price target

+42%to their average target

Analysts' average price target for DaVita is $248, 42% above the Nov 13, 2026 close of $174.56.

DVA growth priced in fair value

pretickt analysis-5%a year, for ten years, and still worth the price

At $174.56 a share, DaVita's free cash flow could shrink about 5% a year for ten years and still be worth the price (Nov 13, 2026).

What is DaVita's P/E ratio?

DaVita's P/E ratio is 13.7 (Nov 13, 2026), near its 3-year median of 14.5. Investors pay 13.7 times DaVita's earnings (Nov 13, 2026), more than for Universal Health Services (8.1), less than for Bio-Techne (66.2), Insulet (24.8) and HCA Healthcare (16.5).

Is DaVita profitable?

DaVita's operating margin was 15% in the 12 months to Sep 30, 2026, against 12% in fiscal 2022. DaVita generated $1.29B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

Who is dumping DaVita stock?

DaVita's executives and directors sold a net $523M of shares in the 12 months to Nov 13, 2026; none bought.

How many employees does DaVita have?

DaVita had 78,000 employees at the end of fiscal 2025, 3% more than a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.